Jason Slingsby’s Post

With Asthma + Lung UK, we are raising awareness about bronchiectasis (BE), an overlooked and poorly understood lung condition. Over the next few weeks, we'll cover what BE is, why it needs attention and the research opportunities available. So what is BE? 🫁 BE is a condition in which the bronchi become abnormally dilated. This results in mucus buildup and creates an environment where bacteria can thrive and airways are blocked, resulting in infection, inflammation, further lung damage, and scarring. Despite being the third most common chronic lung condition in the UK, BE still has no approved effective treatments and diagnosis is inaccurate, long and expensive. It is often mistakenly considered a mild condition, but can lead to significant health issues and frequent hospitalisations, which can have a huge impact on quality of life. The number of people affected by BE is rising in the UK and globally - younger people and children are also increasingly diagnosed with this condition. 📈 We must recognise the growing impact of this condition and work together to increase our efforts to better understand, diagnose and treat this disease. Find out more about our work in BE: https://t.ly/BCNQe

Imagine a reality where every breath is a struggle. Every 5 minutes, someone will die due to a lung condition. Yet research funding and public attention on respiratory diseases is disproportionately low, compared to common illnesses such as cancer or cardiovascular disease. Did you know that: - Lung conditions are the 3rd biggest killer in the UK - 1 in 5 people in the UK will develop a respiratory disease in their lifetime - Lung conditions cost the NHS £10 billion every year - Lung conditions cost the UK £188 billion a year Read our collaborative report with Asthma + Lung UK to hear directly from those living with respiratory disease, as well as clinicians, academics and innovators who have come together to share perspectives and proposals for transforming the future of respiratory diagnostics: https://t.ly/0NRqZ

Launch day for the new LifeArc website! 🚀🎉 This has been my biggest priority since joining the company and I've been lucky enough to work with an amazing team to bring it life! ❤️🙏 https://www.lifearc.org/ The site also debuts our 'what's it like to work here?' video - my second biggest priority since joining. https://lnkd.in/ejJXJaBN This, plus the launch of our new brand, makes it a huge day for our fabulous team! I'm so proud of what we've done together to give LifeArc the glow-up it deserves to make the company's amazing achievements shine even more. ✨ Hannah Rider Meghan Blanksby Katy Haylock Michael Motskin whois:AndyWhite

Our 2 technology transfer fellowships are now open for applications ⬇️ Built for talented scientists looking to transition into the field of technology transfer, you'll get support to grow your skills. Apply as soon as possible using these links: 1️⃣ LifeArc-AUTM Technology Transfer Fellowship (graduate or post-doctoral level): https://t.co/43KGDISMRA 2️⃣ LifeArc Technology Transfer Fellowship (graduate level and/or MBA or equivalent) : https://bit.ly/42zsrKd #Fellowship #TechnologyTransfer #CareersinSTEM

LifeArc and the Bill & Melinda Gates Foundation are teaming up to invest £6 million ($7.2m) in the Grand Challenges African Drug Discovery Accelerator (GC ADDA) programme. 🔗 https://bit.ly/3w4B7Mb Together, we're supporting 5 ground-breaking drug discovery projects led by African scientists over the next 3 to 5 years, including: 🔬 a new malaria treatment, a disease which continues to disproportionately impact Africa, responsible for more than 500,000 deaths in the region 🔬 a novel approach to tackling tuberculosis, which is now the most lethal infectious disease globally 🔬 an exploration into using natural products found in Africa for screening against a range of diseases, including TB, neglected tropical diseases, viral diseases, and malaria 🔬 the formation of the GC ADDA network to help attract investment and strengthen research in Africa 🔬 the establishment of a 'centre of excellence' to help identify drugs likely to be suitable for further development by considering how they are metabolised and processed by the body Our joint funding aims address global research equity challenges and marks a commitment to fostering translational research capabilities on the continent. #GCADDA #GlobalHealth #DrugDiscovery

Hear from the masters on strategies for funding healthcare start-ups at the LifeArc Translational Science Summit on 23 April. Register here for #LATSS2024: https://lnkd.in/epQVG_cu